Medicare has historically not covered weight-loss drugs for obesity alone under standard Part D rules. That has created a gap for patients who need treatment, especially with GLP-1 medications that have become more important in obesity care.
In the STEP 1 trial, adults taking semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks. In the SURMOUNT-1 trial, adults taking tirzepatide 15 mg lost an average of 20.9% over 72 weeks.
The Medicare GLP-1 Bridge is a new short-term CMS pilot program that starts July 1, 2026, and runs through December 31, 2027. It gives eligible Medicare Part D beneficiaries access to certain GLP-1 weight-loss medications for a $50 monthly copay.
If you’ve been waiting for Medicare to cover GLP-1 weight-loss medications, this program is worth knowing about. Below, we’ll explain what the Medicare GLP-1 Bridge is, who qualifies, which drugs are covered, and what patients should ask their doctor before July 1.
What is the Medicare GLP-1 Bridge?
The Medicare GLP-1 Bridge is a short-term program run by the Centers for Medicare & Medicaid Services, also known as CMS. It gives certain people with Medicare Part D access to specific GLP-1 medications for weight reduction and weight maintenance.
The program begins on July 1, 2026, and is scheduled to end on December 31, 2027. CMS calls it a short-term demonstration, which means it is a pilot-style program used to test a different payment approach.
Under the Medicare GLP-1 Bridge, eligible patients pay a $50 monthly copay for a one-month supply. The program does not run through the usual Part D payment system. Instead, CMS uses a central processor to handle prior authorization, claims, and pharmacy payment.
Note: The Medicare GLP-1 Bridge is a Section 402 demonstration. It is not the same as enrolling in a Medicare Part D prescription drug plan.
Beneficiaries who need prescription drug coverage should contact Medicare directly at 1-800-MEDICARE, or 1-800-633-4227. They can also contact their local State Health Insurance Assistance Program, also called SHIP, for help reviewing coverage options.
Who qualifies for the Medicare GLP-1 Bridge?
To qualify for the Medicare GLP-1 Bridge, a person must meet all three main requirements:
Eligible Medicare Part D plan types
A beneficiary must be enrolled in one of the eligible Medicare Part D plan types in calendar year 2026. Eligible plan types include:
-
- Standalone Medicare prescription drug plans, also called PDPs
- Medicare Advantage plans with prescription drug coverage, also called MA-PD plans
- Medicare Advantage HMO plans
- Medicare Advantage HMO-POS plans
- Local and regional Medicare Advantage PPO plans
- Special Needs Plans, also called SNPs
- Employer or union group waiver plans, also called EGWPs
- The Limited Income Newly Eligible Transition program, also called LI NET
Dually eligible beneficiaries may also qualify if they are enrolled in an eligible Part D plan type and meet the prior authorization requirements.
Plan types that are generally not eligible include:
-
- Private fee-for-service plans
- Section 1876 cost contract plans
- Section 1833 health care prepayment plans
- PACE organizations
- Fallback plans
- Religious fraternal benefit plans
However, some beneficiaries in these plan types may still qualify if they are also enrolled in a standalone Medicare Part D prescription drug plan, when applicable.
Eligible GLP-1 medications for the Medicare GLP-1 Bridge
The Medicare GLP-1 Bridge applies only to certain GLP-1 products and formulations. At this time, the eligible GLP-1 drugs are:
Coverage is tied to specific products and National Drug Codes, also called NDCs. An NDC is a unique number used to identify a specific drug product, strength, and package size. This helps Medicare, pharmacies, and drug plans confirm that the exact medication being dispensed is part of the program.
Medicare GLP-1 Bridge clinical criteria
A prescribing provider must submit a prior authorization request and confirm that the beneficiary meets the program’s clinical criteria.
First, the GLP-1 drug must be prescribed to reduce excess body weight or maintain weight reduction. The person must also continue lifestyle changes, including structured nutrition and physical activity, consistent with the FDA-approved label for the drug.
The beneficiary must also be at least 18 years old and meet one of the following BMI and health-condition requirements at the time GLP-1 therapy was started.
| BMI | Other condition needed | Possible eligibility |
|---|---|---|
| 35 or higher | No additional listed condition required | May qualify |
| 30 to 34.99 | Had at least one of the following conditions:
|
May qualify |
| 27 to 29.99 | Had at least one of the following conditions:
|
May qualify |
| Below 27 | Not eligible under Medicare GLP-1 Bridge clinical criteria | Does not qualify |
Does Medicare use starting BMI or current BMI?
For the Medicare GLP-1 Bridge, eligibility is based on the beneficiary’s BMI at the time they started GLP-1 therapy, not necessarily their BMI at the time they apply for the program.
Some people may have already lost weight by the time the Medicare GLP-1 Bridge begins.
For example, a beneficiary may have started GLP-1 therapy in September 2024 with a BMI of 37. By July 2026, their BMI may have dropped to 34. In that case, the prescribing provider can still attest that the person met the BMI 35 or higher requirement when therapy began.
This rule also applies to beneficiaries who started GLP-1 therapy before enrolling in Medicare Part D or before the Medicare GLP-1 Bridge launches on July 1, 2026.
Who does not qualify for the Medicare GLP-1 Bridge?
A beneficiary generally will not qualify for the Bridge if the GLP-1 drug is being prescribed for a condition that is already eligible for Medicare Part D coverage.
These conditions include:
-
- Type 2 diabetes
- Obstructive sleep apnea
- Noncirrhotic metabolic dysfunction-associated steatohepatitis, also called MASH
Beneficiaries with these diagnoses may be able to receive GLP-1 coverage through their regular Medicare Part D plan instead.
How much does the Medicare GLP-1 Bridge cost?
Eligible patients pay a $50 copay for a one-month supply. Each fill must cover either 28 or 30 days, depending on the product. The program does not allow 60-day or 90-day supplies. It also does not allow short transition fills that provide less than a full monthly supply.
The copay does not count toward the patient’s Part D deductible. It also does not count toward the patient’s annual out-of-pocket limit. It will not show on the Part D Explanation of Benefits, and it cannot be lowered by Extra Help. Medicare.gov also says the cost cannot be spread across months through the Medicare Prescription Payment Plan.
This is because the Medicare GLP-1 Bridge sits outside the usual Part D benefit payment flow. The medication is not being paid the same way as a normal covered Part D prescription. CMS says the Bridge will use a central processor to manage prior authorization, claims processing, and pharmacy payment.
How to apply for the Medicare GLP-1 Bridge?
Eligible beneficiaries cannot apply for the Medicare GLP-1 Bridge on their own. To access GLP-1 medications through the program, a medical provider must submit both:
-
- A prescription for an eligible GLP-1 drug
- A prior authorization request showing that the beneficiary meets the program requirements
How does the prior authorization process work?
Prior authorization is the step where the provider confirms that the patient meets the program rules. CMS says the provider must attest that the patient is using the GLP-1 drug for weight reduction and weight maintenance along with ongoing lifestyle modification, including structured nutrition and physical activity, consistent with the applicable FDA-approved label.
Providers will be able to submit prior authorization requests in two ways:
-
- Electronically
- By fax using the Medicare GLP-1 Bridge prior authorization form
Once approved, the prior authorization is valid through December 31, 2027, including refills and dose changes, unless the patient changes GLP-1 drugs.
When can providers submit prior authorization?
Providers can begin submitting Medicare GLP-1 Bridge prior authorization requests on July 1, 2026. Requests will not be accepted before then.
CMS says it will release more details about the process, which will be posted on the CMS Medicare GLP-1 Bridge webpage.
Does the provider need to be enrolled in Medicare?
No. For the Medicare GLP-1 Bridge, a provider does not need to be enrolled in Medicare to write the prescription or submit the prior authorization request.
This is similar to how Medicare Part D works.
However, the provider must not be on the Medicare Preclusion List. If a provider is on the Preclusion List, the drug will not be coverable under the Medicare GLP-1 Bridge for an eligible beneficiary.
The Preclusion List is a CMS list of providers and prescribers who are blocked from being paid for certain Medicare Advantage services or Part D drugs. A provider may be placed on the list because of serious Medicare revocation issues, conduct CMS considers harmful to the Medicare program, or certain felony convictions.
Summary
The Medicare GLP-1 Bridge is one of the biggest Medicare access changes for GLP-1 weight management medications in 2026. It gives eligible Medicare Part D beneficiaries a temporary path to certain GLP-1 drugs for a $50 monthly copay. For patients who could not afford Wegovy, Zepbound, or Foundayo for weight management, this program could make treatment more reachable.
Still, the program has strict limits, and it is temporary. It does not cover every GLP-1 drug or every formulation. It does not apply to patients who already get a GLP-1 through their Part D plan, and it does not apply to patients with type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease because those conditions may use the Part D pathway instead.
If you think you may qualify, review your Medicare drug coverage, check your starting BMI and related health conditions, and talk with your healthcare provider. Your provider must send the prescription and complete prior authorization. If approved, you may be able to access a covered GLP-1 medication through the Medicare GLP-1 Bridge for $50 per month through December 31, 2027.
Frequently Asked Questions
Related Articles
Sources
Medicare GLP-1 Bridge | CMS. (n.d.). https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
Information for Providers | CMS. (n.d.). https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
Information for Pharmacies | CMS. (n.d.). https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-pharmacies
Information for Part D Plans | CMS. (n.d.). https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans
Diabetes Diagnosis & Tests | ADA. (n.d.). https://diabetes.org/about-diabetes/diagnosis
